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Abstract
Microglial neuroinflammatory processes play a primary role in dopaminergic neurodegeneration for Parkinson’s disease
(PD). This can occur, in part, by modulation of glial function following activation by soluble or insoluble modified alphasynuclein (α-syn), a chief component of Lewy bodies that is released from affected dopaminergic neurons. α-Syn is nitrated during oxidative stress responses and in its aggregated form, induces inflammatory microglial functions. Elucidation of these microglial function changes in PD could lead to new insights into disease mechanisms. To this end,
PD-associated inflammation was modeled by stimulation of microglia with aggregated and nitrated α-syn. These activated microglia were ameboid in morphology and elicited dopaminergic neurotoxicity. A profile of nitrated, aggregated
α-syn-stimulated microglia was generated using combinations of genomic (microarrays) and proteomic (liquid chromatography-tandem mass spectrometry, differential gel electrophoresis, and protein array) assays. Genomic studies revealed a substantive role for nuclear factor-kappa B transcriptional activation. Qualitative changes in the microglial
proteome showed robust increases in inflammatory, redox, enzyme, and cytoskeletal proteins supporting the genomic
tests. Autopsy brain tissue acquired from substantia nigra and basal ganglia of PD patients demonstrated that parallel
nuclear factor-kappa B-related inflammatory processes were, in part, active during human disease. Taken together, the
transcriptome and proteome of nitrated α-syn activated microglia, shown herein, provide new potential insights into disease mechanisms.
Keywords: alpha-synuclein, microglia, neuroinflammation, Parkinson’s disease, proteomics
Abbreviations used: ACN, acetonitrile; AD, Alzheimer’s disease; AFM, atomic force microscopy; BG, basal ganglia;
DIGE, differential gel electrophoresis; DMEM, Dulbecco’s modified Eagle’s medium; ex/em, excitation/emission; FBS, fetal bovine serum; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; IP, Immunoprecipitates; LB, Lewy bodies; LCMS/MS, liquid chromatography-tandem mass spectrometry; LPS, lipopolysaccharide; NF-κB, nuclear factor-kappa B; Nα-syn, nitrated alpha synuclein; PBS, phosphate-buffered saline; PD, Parkinson’s disease; PVDF, polyvinylidene fluoride;
RIPA, radioimmunoprecipitation; ROS, reactive oxygen species; SN, substantia nigra; SNpc, substantia nigra pars compacta; TH, tyrosine hydroxylase; α-syn, alpha-synuclein.
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Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by resting tremor, rigidity, bradykinesia, and gait disturbances (Fahn et al. 1998;
Mayeux 2003; Fahn and Sulzer 2004). Presently, 1.5 million Americans are afflicted. Disease incidence rises with
increasing age, with 120/100 000 contracting PD over the
age of 70 (Dauer and Przedborski 2003). Pathologically,
PD is characterized by the progressive loss of dopaminergic neuronal cell bodies in the substantia nigra pars
compacta (SNpc) and their termini in the dorsal striatum
(Hornykiewicz and Kish 1987). These pathological findings commonly parallel microglial activation observed
in association with deposits of aggregated alpha synuclein (α-syn) in intracellular inclusions, known as Lewy
bodies (LB) (Spillantini et al. 1997; Croisier et al. 2005).
Although host genetics and environmental factors affect
the onset and progression of PD (Tanner 1992) significant
clinical, epidemiologic, and experimental data also support a role for microglial inflammation in disease pathogenesis (Forno et al. 1992; Banati and Blunt 1998;McGeer
and McGeer 1998; Mirza et al. 2000;Cicchetti et al. 2002;
Block and Hong 2005; Hong 2005; Wang et al. 2005).
The mechanisms underlying microglial activation in
PD and how it affects neuronal survival is incompletely
understood. One line of investigation is that neuronal
death itself drives microglial immune responses (Giasson et al. 2000; Przedborski et al. 2001; Mandel et al. 2005).
Alternatively, we, as well as others, have proposed that
activation occurs as a consequence of release of aggregated proteins from the cytosol or within LB to the extracellular space. In this way, the death of dopaminergic
neurons leads to release of modified protein aggregates
that activate microglia inciting a lethal cascade of neuroinflammation and neuronal demise (Zhang et al. 2005;
Wersinger and Sidhu 2006). Several lines of experimental
evidence support this contention (Spillantini et al. 1997;
Goedert 1999; Giasson et al. 2000; Kakimura et al. 2001;
Croisier et al. 2005; Lee et al. 2005). First, aberrant expression of α-syn and PD pathogenesis are linked. This is derived from the discovery that mutations and multiple
copies of the gene encoding α-syn (SNCA and PARK1)
are linked to familial early onset PD (Kruger et al. 1998;
Spira et al. 2001; Zarranz et al. 2004; (Singleton et al. 2003;
Chartier-Harlin et al. 2004). Second, oxidation and nitration of α-syn leads to formation of aggregates and filaments that comprise LB (Giasson et al. 2000; Souza et al.
2000). Third, portions of α-syn are secreted rendering it
more vulnerable to aggregation (Lee et al. 2005) and oxidative modification (Kakimura et al. 2001). Fourth, α-syn
itself can activate microglia, inducing reactive oxygen
species (ROS) (Thomas et al. 2007) and subsequent neurotoxicity (Zhang et al. 2005). Fifth, microglial products
including cytokines, chemokines, excitotoxins, and proteins of the classical complement cascade affect a broad
range of neurological diseases (McGeer and McGeer 1998;
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Bal-Price and Brown 2001; Liu and Hong 2003; Block and
Hong 2005). Sixth, endogenous activators of microglia
show a neuroinflammatory fingerprint reflective of what
can occur during PD (Zhou et al. 2005; McLaughlin et
al. 2006). Lastly, attenuation of microglial activation can
protect up to 90% of dopaminergic neurons in PD animal
models (Du et al. 2001; Teismann and Ferger 2001; Wu et
al. 2002; Teismann et al. 2003; Kurkowska-Jastrzebska et
al. 2004; Choi et al. 2005; Vijitruth et al. 2006).
Based on these observations, we investigated changes
in the microglial transcriptome and proteome as a consequence of the cells’ engagement with nitrated and aggregated α-syn (N-α-syn). N-α-syn stimulation of microglia induced morphological cell transformation and
neurotoxic secretions. A N-α-syn-activated ‘microglial
signature’ was determined by gene microarrays, 2D differential in-gel electrophoresis (DIGE), and by cytokine
profiling. N-α-syn induced a microglia inflammatory
phenotype characterized by the expression of neurotoxic
and neuroregulatory factors. Most importantly, the inflammatory signature seen in laboratory assays were, in
part, mirrored in parallel tests performed on postmortem brain tissues from PD patients. These observations,
taken together, serve to support both a ‘putative’ role for
N-α-syn-activated microglia in disease.
Materials and methods
Parkinson’s disease brain tissues
Autopsy materials from the substantia nigra (SN) and
basal ganglia (BG; caudate nucleus and putamen) of 10 patients who died with signs and symptoms of PD, three with
Alzheimer’s disease (AD), and 10 age-matched controls were
secured from the National Research Brain Bank Tissue Consortium. The 10 controls ranged in age from 62 to 91 and died
of diseases unrelated to neurological impairments. This included atherosclerotic and metabolic diseases, infections, and
cancer (Table 1).
An antibody to N-α/β-syn (clone nSyn12, mouse ascites;
Upstate, Charlottesville, VA, USA) that recognizes nitrated human N-α-syn (14.5 kDa) and N-β-syn (17 kDa) was used for immunoprecipitation. Samples of SN from control, AD, and PD
autopsy brain tissues (Table 1) were homogenized in ice-cold
radioimmunoprecipitation (RIPA) buffer, pH 7.4 and centrifuged at 10 000 g for 10 min at 4°C to remove cellular debris.
Protein A/G PLUS-agarose beads (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) were added to 1 mg total cellular
protein and incubated for 30 min at 4°C. Beads were pelleted
by centrifugation at 1000 g for 5 min at 4°C. The supernatants
were incubated overnight at 4°C with 2 μg of primary antibody,
then with Protein A/G PLUS-agarose beads for 6 h on a rotating device at 4°C. Immunoprecipitates (IP) were collected after centrifugation at 1000 g for 5 min at 4°C, washed with phosphate-buffered saline (PBS), and resuspended in 20 μL of 1×
electrophoresis sample buffer.
Nitrated-α-Syn IP (20 μL) were fractionated by 16% Tricine sodium dodecyl sulfate–polyacrylamide gel electropho-
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Table 1. Patient clinical profiles and neuropathological findingsa
Patient Diagnosisb

Gender

1
PD
Female
2
PSP
Male
3
PD
Female
4
PD
Female
5
PD
Female
6
LBD
Male
7
PSP
Male
8
PD
Male
9
PD
Female
			
10
PD
Male
11
AD
Male
			
12
AD
Female
13
AD
Male
a

Agec

Durationd Neuropathologye

78
25
Hypopigmentation and LB formation in SN and locus ceruleus
83
N/A
Cerebral atrophy of frontal and superior temporal
75
9
Idiopathic
89
21
Idiopathic
82
10
Neocortical LB
82
8
Neocortical LB and hippocampal sclerosis
82
24
Degeneration of subcortical nuclei with neurofibrillary tangles
67
17
Hypopigmentation, neuronal loss, gliosis, LB in SN, and locus ceruleus
85
3
Hypopigmentation, gliosis, and neuronal loss in SN, globus 			
pallidus, and caudate-putamen
86
5
Hypopigmentation, LB, neuronal loss in the SN and locus ceruleus
73
8
Neuritic and diffuse plaques and neurofibrillary tangles in neocortex 		
and hippocampus. Neuronal loss in Locus ceruleus.
84
N/A
Remote infarct in the occipital lobe and cerebellum
76
N/A
Senile plaque-predominant AD

Ten non-affected, age-matched controls were used for comparisons in this study; b Final diagnosis at autopsy; c Age at death;
d Duration of disease (years) based on onset of initial symptoms and preliminary diagnosis; e Neuropathology at autopsy.

PD, Parkinson’s disease; PSP, progressive subnuclear palsy; LBD, Lewy body disease; LB, Lewy bodies; SN, substantia nigra;
N/A, data not available; AD, Alzheimer’s disease; N/A, data not available.

resis (PAGE) (Jule Inc., Milford, CT, USA and BIORAD Laboratories Inc., Los Angeles, CA, USA) at constant voltage for
1.5 h. The gels were fixed and stained with Coomasie Blue to
visualize protein bands. Bands corresponding to the molecular weights encompassing 14.5 kDa (α-syn) were excised, digested by trypsin, column purified, and sequenced by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) for
protein validation. Sequenced peptides were distinguished by
peptide matches to the human α-syn sequence (NCBI Accession: AAI08276).
Purification, nitration, and aggregation of recombinant mouse α-syn
Purification, nitration, and aggregation of recombinant
mouse α-syn were performed as previously described (Thomas
et al. 2007). Five individual lots of α-syn were tested for endotoxin by Limulus amebocyte lysate tests and all were below
the limit of detection for endotoxin (< 0.05 endotoxin units).
Amino acid analysis to determine protein concentration using
HPLC was performed by the University of Nebraska Medical
Center Protein Structure Core Facility. Proteins were separated
by PAGE using 4–12% NuPAGE gels (Invitrogen, Carlsbad,
CA, USA). After electrophoresis, the gels were transferred onto
polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA) and probed with primary mouse IgG1 anti-αsyn (1 : 500; Transduction Laboratories/BD Biosciences, Franklin Lakes, NJ, USA) or primary rabbit IgG anti-nitrotyrosine
(1 : 2000; Upstate). Signal was detected with horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (both
from Zymed Laboratories, South San Francisco, CA, USA) using chemiluminescence systems (SuperSignal® West Pico Chemiluminescent Substrate; Pierce Biotechnology Inc., Rockford,
IL, USA). For visualization of the protein by atomic force microscopy (AFM), samples were deposited on mica, glued to a
glass slide, and dried under argon gas flow. The image was
taken in air, height, amplitude, and phase modes using a Mo-

lecular Force Probe 3D controller (Asylum Research Inc., Santa
Barbara, CA, USA).
Isolation, cultivation, and N-α-syn activation of
murine microglia
Microglia from C57BL/6 mice neonates (1- to-2-days old)
were prepared according to well described techniques (Dobrenis 1998). All animal procedures were in accordance with National Institutes of Health guidelines and were approved by
the Institutional Animal Care and Use Committee of the University of Nebraska Medical Center. Brains were removed and
placed in Hanks’ Balanced Salt Solution at 4°C. The mixed glial
cells were cultured for 7 days in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10% fetal bovine serum (FBS),
10 μg/mL gentamicin, and 2 μg/mL macrophage colony stimulating factor (a generous gift of Wyeth Inc., Cambridge, MA,
USA). To obtain homogenous microglial cell populations, culture flasks were gently shaken and non-adherent microglia were
transferred to new flasks. The flasks were incubated for 30 min
to allow the microglia to adhere, and loose cells removed by
washing with DMEM. Microglia were plated at 2 × 106 cells per
well in six-well plates in DMEM containing 10% FBS, 10 μg/
mL gentamicin, and 2 μg/mL macrophage colony stimulating
factor. One week later, cells were stimulated with 100 nmol/L
of aggregated N-α-syn/well or no stimulation for 4 h. Media
were replaced with serum-free DMEM without phenol red or
other additives (Invitrogen) and incubated for 24 h in a 37°C,
5% CO2 incubator.
Inflammatory genomic and PCR assays
RNA from N-α-syn stimulated primary murine microglial
cells and unstimulated control was extracted with TRIzol (Invitrogen), column purified (Qiagen, Valencia, CA, USA), precipitated with ammonium acetate, amplified and labeled using
the T7-based TrueLabeling-AMP 2.0 kit (Superarray, Frederick,
MD, USA). The resultant cRNA was hybridized to an oligo-
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based microarray for mouse general pathway (Superarray
#OMM-014) and nuclear factor-kappa B (NF-κB)-related genes
(Superarray #OMM-025). The arrays were washed, incubated
sequentially with streptavidin-bound alkaline phosphatase
and chemiluminescent substrate before exposure to X-ray film.
Subsequent analysis of the microarrays was performed using
the GEArray expression analysis suite (Superarray).
Total RNA obtained from analysis of the microglial transcriptome was reverse transcribed with random hexamers and SSII reverse transcriptase (Applied Biosystems, Foster City, CA, USA). Murine-specific primer pairs were: Ccl2:
CCCCAAGAAGGAATGGGTCC and GGTTGTGGAAAAGGTAGTGG; Il1β: GTTCCTTTGTGGCACTTGGT and CTATGCTGCCTGCTCTTACTGACT; Il10: CAGTTATTGTCTTCCCGGCTGTA and CTATGCTGCCTGCTCTTACTGACT; Ifng:
TTTGAGGTCAACAACAACCCACA
and
CGCAATCACAGTCTTGGCTA; and Nos2: 5’-GGCAGCCTGTGAGACCTTTG-3’ and 5’-GAAGCGTTTCGGGATCTGAA-3’. TaqMan gene expression assays specific for murine Tnf, Tnfrsf1a,
Stat1, Rela, Bdnf, and Gdnf were purchased from Applied Biosystems, and normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression. Tissue samples obtained from
PD and control patients were snap frozen on dry ice and stored
at −80°C. RNA was prepared from the samples using TRIzol
reagent (Invitrogen) and purified with the RNeasy Mini Kit
(Qiagen), prior to cDNA synthesis. Human specific primers
for TNF, TNFRSF1A, STAT1, NFKB1, RELA, BDNF, and GDNF
were analyzed using TaqMan gene expression assays. Gene
expression was normalized to the housekeeping gene Gapdh.
Real-time quantitative PCR was performed with cDNA using
an ABI PRISM 7000 sequence detector (Applied Biosystems).
Reverse SYBR Green I detection system was used, and the reactions generated a melting temperature dissociation curve enabling quantitation of the PCR products.
Cytokine arrays
Microglia were plated at a density of 2 × 106 cells/well in a
six-well plate and stimulated with 100 nmol/L aggregated Nα-syn, and 100 ng/mL lipopolysaccharide (LPS, Escherichia coli;
Sigma-Aldrich, St. Louis, MO, USA) in serum-free media. Fifty
microliter aliquots were collected at 8, 24, and 72 h of incubation in triplicate and frozen at −80°C. For assay, the samples
were analyzed using the BD Cytometric Bead Array Mouse Inflammation Kit (BD Biosciences, San Jose, CA, USA) according
to the manufacturer’s protocol. Samples of culture supernatants
from microglia were diluted 1 : 3 and 1 : 10 in assay diluent and
analyzed for cytokine concentration with a FACSCalibur flow
cytometer (BD Biosciences). Concentrations of cytokines were
determined from a standard curve created with serial dilutions
of the cytokine standards provided by the manufacturer.
Neurotoxicity assays
MES23.5 cells, kindly provided by Dr Stanley Appel, were
cultured in 75-cm2 flasks in DMEM/F12 with 15 mmol/L
HEPES (Invitrogen) containing N2 supplement (Invitrogen),
100 U/mL of penicillin, 100 μg/mL streptomycin, and 5% FBS.
Cells were grown to 80% confluence then co-cultured at 1 : 1
ratio with previously plated microglial cells. To assess cell viability microglia cells were plated at a density of 5 × 104 cells
on sterile glass coverslips, and co-cultures were prepared with
a 1 : 1 ratio microglia: MES23.5 cells. After 24–48 h, cells were
stimulated with aggregated 100 nmol/L N-α-syn or 100 nmol/
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L α-syn for 4, 8, 24, and 72 h. CD11b+ microglial cells were
distinguished from MES23.5 cells by APC-conjugated CD11b
(1 : 200; Invitrogen) immunocytochemistry. For tyrosine hydroxylase (TH) cytostaining, cells were fixed in 4%p-formaldeyde, permeablized, and blocked in 2% normal goat serum
with 0.25% Triton X-100 in PBS for 30 min, and probed with
rabbit polyclonal anti-TH (1 : 1000; EMD Biosciences Inc., San
Diego, CA, USA), followed by FITC goat anti-rabbit IgG. For
western blot analysis, 10 μg of protein sample from cell lysates
of each treatment group was loaded onto a 12% NuPAGE Bis–
Tris gel (Invitrogen). Following transfer onto a PVDF membrane, the membrane was blocked and then probed overnight
with anti-TH (1 : 1000). Signal was detected with horseradish
peroxidase-conjugated anti-rabbit IgG (1 : 10 000; Zymed Laboratories) using chemiluminescence system (SuperSignal®
West Pico Chemiluminescent substrate; Pierce Biotechnology
Inc.). Densitometric analysis was performed using ImageJ software and normalized to β-actin (1 : 1000; Abcam, Cambridge,
MA, USA). Assays for viable and dead mammalian cells (Live/
Dead Viability/Cytotoxicity; Invitrogen) were performed according to manufacturer’s protocol. The protocol was revised
so that the concentration of each dye was 1 μmol/L to avoid
high background. Live cells were distinguished by the uptake
of calcein acetoxymethyl ester to acquire a green fluorescence
[excitation/emission (ex/em) 495/515 nm], while dead cells
acquired a red fluorescence (ex/em 495/635 nm) because of the
uptake of ethidium homodimer-1. Cell enumerations were performed using fluorescence microscopy (200× magnification)
and a M5 microplate fluorometer (Molecular Devices, Sunnyvale, CA, USA) (Limit 1 ex/em 490/522 nm and Limit 2 ex/
em 530/645 nm). The number of viable MES23.5 cells in each
treatment group was normalized as the percentage of surviving cells in unstimulated culture controls.
Protein purification, 2D DIGE, and DeCyder
analyses
Cell lysates of microglia were prepared with 5 mmol/L
Tris–HCl, pH 8.0, 1% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate and a cocktail of protease inhibitors
(Sigma-Aldrich). Protein content was quantitated using a DC
Protein Assay (BioRad, Hercules, CA, USA). Factors known to
interfere with isoelectric focusing (first dimension separation
in 2D sodium dodecyl sulfate–PAGE) such as salts and detergents were removed from cell lysates using the 2D Cleanup kit
(GE Healthcare, Piscataway, NJ, USA) according to manufacturer’s protocol. Protein concentration was determined using
2D Quant (GE Healthcare). Samples of control and stimulated
cell lysates (25 μg of each lysate) were labeled with 400 pmol of
CyDye 2. A 50 μg protein sample of control cell lysate was labeled with 400 pmol of CyDye 3; and a 50 μg protein sample
of stimulated cell lysate was labeled with 400 pmol of CyDye
5. Labeling was performed following the manufacturer’s protocols. The samples were pooled, resuspended in rehydration
buffer to a total volume of 450 μL, then loaded onto an immobilized pH gradient strip, and left for 18 h for rehydration. In
the first dimension, samples were run in IPGphor and in Ettan DALTsix electrophoresis apparatus (GE Healthcare) for the
second dimension. CyDye 3- and CyDye 5-derivatized proteins
were detected in gels using a Typhoon 9400 Variable Mode Imager with ex–em filters at 540/590 nm for CyDye 3 dyes and
620/680 nm for CyDye 5 dyes (GE Healthcare). Analysis of CyDye 3-CyDye 5 image pairs, adjustment to CyDye 2 control im-
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ages, and detection of protein spots with relative spot volumes
were performed using DeCyder software (GE Healthcare) to
locate and analyze multiplexed samples within the gel. Selected protein spots of interest were excised from the 2D gel using an Ettan Spot Picker. The proteins from gel pieces were digested with trypsin, as described below, and resultant peptides
were analyzed using LC-MS/MS system (ThermoElectron Inc.,
Waltham, MA, USA). Protein identification was completed using BioWorks 3.1 software.

using ImageJ and normalized to Gapdh (1 : 5000; Santa Cruz Biotechnology Inc.) level in the same sample.

In gel tryptic digestion and protein
identification by LC-MS/MS
Specific protein spots were excised from the gels by an automated Ettan spot picker. Following column purification (ZipTip CU-18; Millipore) with 50% acetonitrile (ACN), 50 mmol/L
NH4HCO3/50% ACN, and 10 mmol/L NH4HCO3/50% ACN,
gel pieces were dried and incubated with trypsin (100 ng/μL)
(Promega, Sunnyvale, CA, USA) for 12–18 h. Samples were extracted by 0.1% trifluoroacetic acid/60% ACN, pooled, and
dried.
Dried peptide samples were reconstituted in 0.1% formic
acid/HPLC-grade water, detected on a ProteomeX LCQTM
DECA XP Plus mass spectrometer (ThermoElectron Inc.), and
identified using BioWorks 3.1SR software. Proteins identified by
peptides having a Unified Score (BioWorks 3.1SR, ThermoElectron Inc.) greater than 3000 were marked for further analysis.

Results

Nuclear/cytosol fractionation
Cell lysates were prepared from SN of PD and control patients by homogenization in PBS. Cells were collected following centrifugation at 500 g for 5 min. Cytosol and nuclear fractions were prepared using the Nuclear/Cytosol Fractionation
Kit (BioVision, Mountain View, CA, USA) according to manufacturer’s protocol.
Western blot assays
Protein was prepared from cell lysates in RIPA buffer supplemented with protease inhibitors (Pierce Biotechnology Inc.).
Protease inhibitor cocktail was added to each conditioned media sample fraction prior to processing. Following centrifugation at 10 000 g for 10 min, the supernatants were removed and
allowed to dialyze against water overnight. Tissue samples obtained from PD and control patients were snap frozen on dry ice
and stored at −80°C. Protein lysates were prepared from individual samples through homogenization in RIPA buffer supplemented with protease inhibitors (Pierce Biotechnology Inc.). Protein quantification was performed using the bicinchoninic acid
kit (Pierce Biotechnology Inc.). Protein concentration of each
sample was determined using a calibration curve generated
from purified bovine serum albumin. A total of 20 μg of each
sample was loaded onto 4–12% Bis–Tris NuPAGE gels (Invitrogen) and transferred onto PVDF membranes (BioRad). Primary
antibodies to calmodulin (1 : 1000) and 14-3-3σ (1 : 200) (Millipore), biliverdin reductase (1 : 5000), thioredoxin (1 : 2000), β-actin (1 : 5000), and α-tubulin (1 : 5000) purchased from Abcam, lplastin (1 : 1000), α-enolase (1 : 1000), glutathione-S-transferase
(1 : 1000), and NF-κB p65 and p50 (1 : 200) purchased from Santa
Cruz Biotechnology Inc. were used for analyses. Blots were
probed with the respective horseradish peroxidase-conjugated
secondary antibodies (1 : 5000; Invitrogen) and detected using
SuperSignal West Pico Chemiluminescent substrate (Pierce Biotechnology Inc.). The intensity of protein bands was quantified

Statistical analyses
All values are expressed as mean ± SEM. Differences
among means were analyzed by Student’s t-test or by one-way
anova followed by Bonferroni post hoc testing for pair-wise
comparison.

Aggregated N-α-syn and microglial activation: laboratory and pathological studies
To investigate the mechanisms by which N-α-syn-mediated microglial activation affects dopaminergic neurodegeneration, we created a cellular model that would
reflect the salient features of neuroinflammation as it
could occur in PD. To this end, we first determined if
N-α-syn was present in regions of brain where microglial activation is known to be present in PD. Whole cell
lysates consisted of several protein bands following gel
electrophoresis (data not shown) and Coomassie staining (data not shown). IP assays performed from SN tissues of PD patients using a primary antibody against
nitrated α/β-synulcein showed a greater than twofold
increase in intensity of the protein band corresponding
to 14–14.5 kDa (p < 0.001) than that present in control patients (Figure 1a) or in patients diagnosed with AD (data
not shown) along with higher molecular weight species
greater than 17 kDa (data not shown). Peptide sequence
analyses by LC-MS/MS revealed that the protein band
encompassing the 14–14.5 kDa of the anti-N-α-syn IP
contained peptides with sequence homology to human αsyn in SN samples recovered from PD brains (Figure 1a,
highlighted sequences). Interestingly, such sequence homologies to α-syn were not identified from 14 to 14.5 kDa
proteins in either control or AD samples. Thus, we next
sought to develop an in vitro model to reflect conditions
present in an affected human host, but using the murine
analog. Here, recombinant mouse α-syn was purified,
nitrated, and aggregated for use as a microglial stimulant. Western blot assays showed cross-linking of N-αsyn monomers (Souza et al. 2000) and higher molecular
weight aggregates, thus verifying the nitration and aggregation of α-syn (Figure 1b). The aggregated N-α-syn
contained a substantially reduced monomeric band (corresponding to a band at ~14 kDa) but higher molecular
weight banding aggregates. Analysis of protein aggregation was also assessed by AFM. Samples of N-α-syn contained low numbers of globular aggregates (2–6 nm in
height) prior to aggregation. However, following aggregation, N-α-syn was present predominately as oligomers
(2–6 nm in height). In addition, there were few protofibrils (1.5–2.5 nm in height), filaments, and fibrils (~5–
8 nm in height) present (Figure 1c). Non-nitrated α-syn
was present in similar configurations (data not shown).
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Figure 1. α-Syn nitration, aggregation, and microglial activation. (a) Coomassie stain of anti-N-α/β-synuclein immunoprecipitation from SN from control and PD brains. Arrowhead reflects the area excised from gel and submitted for LC-MS/MS analysis.
Equal concentrations of proteins from control and experimental brain tissues served as loading controls. Peptides obtained by
LC-MS/MS that matched human α-syn are highlighted within the full-length sequence. (b) Western blot analyses of recombinant
mouse α-syn and derivatives. Lane 1 is a nitrotyrosine modified protein provided by the manufacturer. Lanes 1–3 were blotted
and probed with anti-nitrotyrosine, and lanes 4–6 were probed with anti-synuclein. (c) AFM images are shown for unaggregated
(0.4 × 0.4 mm) and aggregated N-α-syn (1.6 × 1.6 mm). Arrow indicates location of inset photomicrograph. Scale bar corresponds to height of aggregates on the interface. (d) Microglial morphology after exposure of microglia to media alone (control,
left) or 100 nmol/L N-α-syn (center), and N-α-syn stimulated microglia in co-culture with MES23.5 cells (right; scale bar: 25 μm).
Cells were stained with calcein AM to detect viable cells. (e) Cytokine bead arrays were used for flow cytometric analysis of supernatants from unstimulated microglia (control, open box) and microglia stimulated with either 100 nmol/L N-α-syn (closed triangle) or 100 ng LPS (closed circle) (n = 3, p < 0.01 vs. aControl and bLPS at each corresponding time point).

We next evaluated the stimulatory effects of N-α-syn on
microglia. The dose of 100 nmol/L (14.5 ng protein/mL)
was selected based on previous extensive works performed in our laboratories demonstrating that, following a dose-response of N-α-syn, 100 nmol/L (50% over
control) is required to induce substantive ROS from activated microglial cells (Zhang et al. 2005; Thomas et al.

2007) as well as cytotoxicity. ROS production was slightly
decreased in comparison with either 50 or 500 nmol/L of
N-α-syn. While native α-syn is ubiquitously expressed,
the physiological concentration of N-α-syn in disease has
not been elucidated. However, based on concentrations
of modified α-syn in affected PD brain tissues, 100 nmol/
L concentration is at physiologically relevant levels (Hal-
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liday et al. 2005) and is below that detectable by immunohistochemistry in neuronal inclusions within the SN
of PD brains (≥ 100 ng). Phenotypic transformation into
an ameboid morphology commonly follows microglial
activation with different pro-inflammatory stimuli (Giulian et al. 1995; Vilhardt 2005). Thus, we examined if
changes in microglial morphology would be elicited following N-α-syn activation. Resting microglia were both
round and ellipsoid shaped with retracted processes that
were characteristic of a relatively quiescent phenotype
(Figure 1d). In contrast, N-α-syn activated microglia assumed a more ameboid appearance with extensive processes, characteristic, in part, of an activated phenotype.
N-α-syn-stimulated microglia co-cultured with MES23.5
cells acquired a rod-like appearance and further extension of processes.
We recently demonstrated that 100 nmol/L of aggregated N-α-syn could activate microglia to produce copious amounts of ROS (Thomas et al. 2007). In contrast,
unaggregated N-α-syn or minced neuronal membrane
fractions failed to induce significant amounts of ROS
above control levels. This suggested that the microglial
response to N-α-syn was specific and could not be elicited in response to unaggregated protein or by phagocytosis under the same conditions. Therefore, we assessed
the extent of the neuroinflammatory phenotype induced
by N-α-syn stimulation of microglia. Quantification of
common cytokines and chemokines that are secreted in
response to inflammatory stimuli was performed by cytometric bead array. LPS-activated microglia served as a
positive control. Stimulation with N-α-syn enhanced the
secretion of TNF-α, IL-6, MCP-1 (Figure 1e), and IFN-γ
(data not shown) compared with basal levels observed
in unstimulated microglia. These results are consistent
with the induction of an inflammatory microglial phenotype following N-α-syn stimulation. The parallels between N-α-syn and LPS-induced cellular effects support
a commonality for innate immune responses in disease
and suggest that these pro-inflammatory processes may
be common among mononuclear phagocytes that recognize disparate activators.
N-α-syn-stimulated microglia are neurotoxic to MES23.5 dopaminergic cells
To determine the effect of N-α-syn-activated microglia on neuronal survival, the dopaminergic MES23.5 cell
line was used as an indicator for cytotoxicity measurements by co-culture with stimulated and unstimulated
microglia. MES23.5 cell death was determined by measuring immunoreactivity for the rate-limiting enzyme
in dopamine synthesis, TH, expressed by MES23.5 cells,
and the Live/Dead cell assay. During stimulation with
100 nmol/L N-α-syn, the number of TH+ cells declined
in the stimulated cultures, resulting in a significant diminution in TH-immunoreactive cells (8 h: 74.6% of control; 24 h: 53.4% of control, p < 0.01; 72 h: 48.5% of con-
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trol, n = 6, p < 0.01). Western blot analysis confirmed
this observation, as TH expression decreased in a timedependent manner over the course of N-α-syn stimulation (TH+/β-actin ratio at 8 h: 94.6% of control; 24 h:
86.2% of control; 72 h: 64.9% of control, p < 0.01). Analysis of cell viability with the Live/Dead cell assay demonstrated that stimulation of microglia with 100 nmol/
L of N-α-syn followed by MES23.5 co-culture resulted
in remarkable reduction of viable cells with concomitant increase in dead MES23.5 cells; whereas, fewer dead
cells were observed in co-cultures with microglia stimulated with α-syn (non-nitrated) after 24 h (Figure 2a).
Percentage of MES23.5 cell survival was less in co-cultures with microglia stimulated with α-syn (83%) and Nα-syn (58%) compared with unstimulated controls (95%)
at 72 h (Figure 2b). The more sensitive fluorometric analysis revealed as early as 24 h after stimulation a similar pattern of progressive decline in viable cells in the
presence of α-syn and N-α-syn stimulated microglia to
76% and 65% of controls at 24 h of stimulation, respectively (Figure 2c). Moreover, N-α-syn-mediated cytotoxicity was restricted to MES23.5 cells, as stimulation of microglia in the absence of MES23.5 cells neither affected
microglial survival (Figure 2d) nor yielded a significant
difference in the number of dead CD11b+ cells between
control and stimulated cultures (data not shown). In addition, cytotoxicity of MES23.5 cells was not elicited with
N-α-syn in the absence of microglia (Figure 2d). Furthermore aggregation of N-α-syn was necessary for inducing microglia cytotoxicity (Figure 2d). Importantly, a decrease in the cell survival was observed when microglia
were stimulated with either aggregated α-syn (93%) or
N-α-syn (86%) for 24 h, and co-cultured with MES23.5
cells in transwell inserts, but not unaggregated protein.
MES23.5 cultures incubated with supernatants obtained
from microglia stimulated with either α-syn or N-α-syn
resulted in decreased cell survival (89% and 84%, respectively) compared with supernatants from unstimulated
microglia (Figure 2e).
NF-κB gene expression and nuclear translocation in PD
NF-κB pathway activation is critical for the initiation
of inflammatory events including the production of inflammatory cytokines and chemokines linked to inflammation and microglial activation. We hypothesized that
acquisition of such an inflammatory phenotype begins
with induction of gene products that ultimately leads to
neurotoxic factor production, cell migration, and apoptosis. To determine the extent to which this pathway was
operative in PD, the SN and BG of PD brains (clinical and
neuropathological profiles shown Table 1) and controls
(those without neurological disease) were analyzed for
NF-κB-related genes as well as neurotrophin expression
(Figure 3). Increases, albeit modest, were seen in NFKB1
expression from samples of SN from PD patients com-
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Figure 2. N-α-syn-stimulated microglia decrease dopaminergic cell survival. (a) Representative photomicrographs of Live/Dead
assays of unstimulated or N-α-syn stimulated microglia co-cultured with MES23.5 cells for 24 h. Viable cells appear green and
dead cells are red. (scale bars: 25 μm). (b and c) N-α-syn-induced microglial inhibition of cell survival. A time-course for cell survival is shown for MES23.5 cells and microglia co-cultured in the presence of media alone (Con, box), 100 nmol/L unmodified αsynuclein (α-syn, triangle), or 100 nmol/L N-α-synuclein (N-α-syn, circle). Cell viability was quantified using the Live/Dead assay by (b) cell count (n = 9 fields, p < 0.01 compared with a0 h and ball treatment groups at corresponding time point), and by
(c) fluorometric analysis (n = 9 fields, p < 0.01 compared with a0 h and ball treatment groups at corresponding time point). (d)
Cell survival of MES23.5 cells in co-culture with microglia after 72 h of stimulation with either α-syn or N-α-syn (n = 9, p < 0.01
compared with aall treatment groups and bα-syn stimulated microglia). (e) Influence of secretory factors from microglia stimulated with either α-syn or N-α-syn for 24 h on MES23.5 cells was determined. Cell survival was assessed following incubation
with supernatants or in transwell format for 24 h (n = 3, p < 0.01 compared with aall treatment groups and bα-syn-stimulated
microglia).
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Figure 3. Cellular activation and oxidative stress pathways in PD brain tissues. Tissue samples from the SN and BG of control
(filled bars) and PD patients (open bars) (Table 1) were evaluated by qRT-PCR for expression of NF-κB pathway associated genes.
The relative expression of a gene was normalized to GAPDH in the same sample and values are represented as mean ± SEM (a
p < 0.05, b p < 0.01, and c p < 0.001 compared with samples from control patients, n = 8–10 patients per group).

pared with controls; whereas, no significant difference
was observed for RELA expression (data not shown).
However, an eightfold increase in TNF expression was
observed in the SN and BG together with a twofold increase in expression of its receptor TNFRSF1A. STAT1
was minimally decreased in PD brains. Similarly, analysis of AD brain tissues as a control for neuroinflammatory pathology also revealed a moderate induction of
NF-κB transcription factors NFKB1 and RELA, while TNF
expression was increased 40- and 10-fold in the SN and
BG along with modest elevations of STAT1 in AD brain
tissues compared with controls (data not shown). Based
on these findings, we reasoned that a compensatory trophic mechanism could be operative in PD. Indeed, BDNF
was shown to be increased greater than sixfold in the SN
and twofold in the BG in PD. Consistent with recent observations by others (Backman et al. 2006), GDNF was increased greater than 10-fold in the BG but no significant
changes were observed in the SN.
A recent investigation by immunofluorescence analysis of midbrain sections revealed a marked increase in
expression of NF-κB p65 in the SN of PD patients compared with controls, which co-localized to CD11b+ microglia in addition to affected neurons (Ghosh et al. 2007).
In the current study cytosolic and nuclear fractions were
prepared from the lysates of SN of PD and control brain
tissues, and lysates analyzed for NF-κB protein subunits
p50 and p65. Increased expression of NF-κB subunits in
both the cytosolic fractions and nuclear fractions were
observed in PD brain tissues (Figure 4). Phosphorylation
of serine 536 (pS536) critical for RelA/p65 transcriptional
activity was also increased in PD brain tissues.

N-α-syn-activated microglia and the PD
transcriptome are linked through NF-κB
The increased expression of NF-κB transcription identified in the SN of PD brains and the microglial response to
N-α-syn stimulation that were consistent with inflammatory responses suggested that one major signaling pathway induced by N-α-syn involves NF-κB activation. Use
of a general microarray confirmed that NF-κB expression
was increased by stimulation with N-α-syn (Figure 5a).
Using NF-κB-focused microarrays (Figure 5b, Table 2),
we showed increased expression of genes encoding proinflammatory cytokines, including Tnf, Ccl2, Il6, and Il1β.
Also induced were those genes encoding the NF-κB transcription factor subunits, Nfkb1, Nfkb2, and Rela. In addition, N-α-syn induced genes involved in other pathways,
particularly those of the mitogen-activated pathway, as
indicated by the induction of the immediate early genes,
Fos and Raf1. At 4 h post-stimulation, expression of most
NF-κB-related genes peaked. The majority of genes induced at 1 h remained elevated, with the addition of the
apoptosis-regulatory genes Card10 and Casp8. The NF-κB
inhibitor, Nfkbia, was also induced (data not shown) but
may become apparent only after removal or clearance
of the stimulus, as Ikbkb expression was also induced at
this time. Removal of N-α-syn from microglial cells after 4 h of stimulation reduced most NF-κB genes to prestimulatory levels. At 8 and 16 h following removal of Nα-syn from culture, several apoptosis-regulatory genes
(Card10, Card11, and Cflar) were induced as well as genes
for receptors of cell activation and NF-κB stimulation including Tnfrsf1a and Cd40. These results were similar
but lesser in magnitude than stimulation of microglia
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Figure 4. NF-κB translocation in PD. Expression of NF-κB subunits p50/NFKB1 and p65/RELA
proteins were evaluated by western blot analysis
from whole tissue lysates (top), cytosolic fractions
(middle), and nuclear fractions (bottom) of SN
from control and PD patients (Table 1). Expression of phosphorylated RELA/p65 [NF-κB pS536]
within the nuclear fraction was also assessed.
The mean densitometric values were determined
with ImageJ software and normalized to GAPDH
expression in the same sample (bottom). Values
are represented as the mean density ± SEM for
four patients/group and p-values of Student’s ttest for pair-wise comparisons of densities from
control (open bars) and PD (filled bars) patients
are * p < 0.05 and ** p < 0.005. Blots are representative of two independent experiments (n = 4
patients per group).

with LPS (Figure 5b, Table 3). Consistent with microarray analyses, quantitative RT-PCR analyses of Tnf, Il1β,
and Ccl2 genes indicated very high levels of transcripts
for these cytokines during stimulation by N-α-syn (10-,
3097-, and 16-fold increases, respectively) over pre-stimulatory levels (Figure 5c). Verification of gene expression during stimulation of other, less abundant, NF-κBrelated genes were achieved, including Tnfrsf1a (6.2-fold
increase), Stat1 (2.3-fold increase), and Rela (3.6-fold increase). N-α-syn stimulation also increased expression of
Nos2 (inducible nitric oxide synthase) and Ifng (data not
shown), both regulated by NF-κB activation. Expression
of the neurotrophins Bdnf and Gdnf were also increased
following N-α-syn stimulation.
N-α-syn-activated microglial proteome
shows a reactive inflammatory phenotype
Analysis of the N-α-syn microglial transcriptome
showed differential gene regulation and induction of the
NF-κB pathway, indicative of an inflammatory microglial
phenotype. Activation of this pathway influences down-

stream expression of proteins involved in processes including inflammation, immune regulation, survival, and
proliferation. Protein expression obtained from cell lysates were analyzed following 2, 4, and 8 h of stimulation with 100 nmol/L N-α-syn to assess the translation of
differences in gene induction to intracellular protein expression. Two-dimensional DIGE was used to compare
protein expression profiles of unstimulated microglia
(control) and N-α-syn-stimulated microglia (Figure 6). A
complete listing of all proteins identified by LC-MS/MS
is contained within Table 3.
Stimulation with N-α-syn resulted in differential expression of several proteins that are likely a consequence
of NF-κB-related signaling pathways (Table 3) as soon
as 2 h after stimulation. Many proteins differentially expressed could be attributed to oxidative stress, including
the down-regulation of aconitase as well as the up-regulation of peroxiredoxin-1, -4, -5, superoxide dismutase,
and heat-shock protein 70.
After 4 h of N-α-syn-stimulation, proteins decreased
included several cytoskeletal proteins including β-actin,
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Figure 5. Microarray analysis of N-α-syn-stimulated microglia. RNA was isolated from microglial cells stimulated with 100 nmol/
L N-α-syn or 100 ng/mL LPS from which cDNA was made and amplified. (a) General pathway-focused microarray revealed involvement of NF-κB signaling pathways. (b) Focused arrays were utilized for regulation of NF-κB associated genes for microglia
that were unstimulated (0 h Control) or stimulated with 100 nmol/L N-α-syn or 100 ng/mL LPS for 1 h and 4 h, respectively. Red
and green boxes indicate genes that were induced by stimulation at 1 and 4 h, respectively. Identified genes and their expression
levels are shown in Table 1. (c) qPCR of mRNA from samples confirmed representative inductions for genes (rank and file position in microarry) Ccl2 (F2), Il1β (H5), Tnfrsf1a (D13), Stat1 (11E), Rela (10F), Tnf (Α13), and Nos2. Gene expression for the
neurotrophins Bdnf and Gdnf were also assessed by qPCR from the same mRNA/cDNA samples [n = 3, p < 0.01 compared with
a0 h control (C) and bLPS at corresponding time point].

cofilin-1, profilin-1, tropomysin-3, and vimentin. The putative functions of other proteins decreased in N-α-synstimulated microglial lysates were found to be involved
in cell adhesion and actin microfilament attachment to

the plasma membrane (vinculin, coronin-1A, and adenylyl cyclase-associated protein 1), glycolysis and growth
control (α-enolase), and migration (galectin 3 and macrophage migration inhibitory factor) (Walther et al. 2000;
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Table 2. N-α-syn- and LPS-stimulated microglial transcriptomea
N-α-syn (h)
Gene

Common name

NCBIb

4

8

LPS (h)
16

4

8

Transcription factors
Crebbp
Crebbp
Fos
c-Fos
Jun
c-Jun
Nfκb1
NFκB p50
Rel
Rel
Rela
NFκB p65
Smad3
Smad3

12914
2.45			
2.6		
14281
> 20					
16476
2.28					
18033
2.08			
7.6		
19696
6.5			
15.4
4.3
19697
4.59					
17127		
−2.5				

Signal transduction
Htr2b
Serotonin receptor
Ikbkb
Ikbkb
Ikbke
Ikbke
Mapk3
Mapk3
Map3k14
Map3k14
Plk2
Plk2
Raf1
Raf-1
Stat1
Stat1
Tbk1
Tbk1
Tgfbr2
TGF-beta receptor 2
Tlr2
Toll-like receptor 2
Tlr3
Toll-like receptor 3
Tlr8
Toll-like receptor 8
Tnfrsf1a
TNFR1

15559
3.56
−2.38				
16150
5.19			
2.7		
56489
3.09					
26417
2.67					
53859		
−2.34
−2.4
−2		
20620		
2.39
2.04
3.1
4.1
110157
5.63					
20846
5.56
3.5		
5.1
5.2
56480
4.24					
21813		
−3.91		
−2.8
−2.6
24088
7.38		
2.43			
142980		
−2.2				
170744
2.38					
21937		
2.03
4.06
5.7
8.6

Inflammation
Tnf
Ccl2

21926
20296

Il10
Il1b
Il6
Tnfrsf5
Tnfrsf7
Traf6
Apoptosis
Card10
Card11
Card4
Casp1
Casp8
Cflar
Ripk1

Malt1
Ripk2
Tnfaip3
Tnfsf10
Tradd
Traf3
Other
Csf2
Dusp1

TNF-alpha
Chemokine ligand 2
(MCP-1)
Interleukin 10
Interleukin 1-beta
Interleukin 6
CD40
Tnfrsf7
Traf6

2.25					
36.43
3.83
2.68
15.1
14.7

16

2.5
3.2
4.6

2.7

14.5

16153
2.31			
5.8
4
16176
> 20
3.02
2.27
10.7
10.1
16193
13.09		
2.57
78.1
25.4
21939
9.91
25.6
7.23
145.1
135.5
21940		
−3.14				
22034		
−2.71				

3.1
9.9
2.3
45.7

Card10
105844
5.62
8.34
7.9
10.7
10.6
Card11
108723			
2.63			
NOD1
107607
7.44			
8.6
5.5
Caspase 1
12362
4.3					
Caspase 8
12370
2.49					
Clarp
12633
19.65
2.22
2.08
8.6
7
Receptor (TNFRSF)19766		
−2.6		
2.1
interacting serinethreonine kinase 1			
Malt1
240354
6.1			
6.2		
Cardiak
192656
6.16			
9.5
7.3
A20
21929			
6.55
8.9
3.2
TRAIL
22035		
10.06				
Tradd
71609			
2.43
2.2		
CD40BP
22031
2.03					

11.1

GM-CSF
Dusp1

12981
19252

3.76					
3.15			
6
6.2

5.4

6.7

5.3
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Table 2. (continued)
N-α-syn (h)
Gene
Hmgb1
Icam1
C3
Irak1

Lta
a

Common name

NCBIb

4

8

LPS (h)
16

4

8

Hmgb1
15289
2.96			
2.2		
Icam1
15894
12.79
4.97
3.46
5.2
4.8
Complement component 3 12266
2.02					
Interleukin-1 	
16179
2.19
receptor-associated
kinase 1						
Lymphotoxin A
16992
3.09			
22.8		

Values represent fold-change versus unstimulated controls;

Chandrasekar et al. 2005). Annexin A3 is an inhibitor of
phospholipase A2 and a promoter of apoptosis of inflammatory cells (Parente and Solito 2004), and was also
down-regulated. The antioxidant glutaredoxin-1 was also
decreased in cell lysates compared with unstimulated
controls (Table 3). Four of the proteins increased in stimulated cell lysates affect intracellular calcium signaling,
storage, and cell cycle regulation (swiprosin 1, calmodulin, calreticulum, and nucleophosmin 1) (Parente and
Solito 2004; Vuadens et al. 2004; Meini et al. 2006).
By 8 h, 73 proteins were differentially expressed.
Thirty-three proteins were decreased including all cytoskeletal proteins down-regulated at 4 h, vimentin and βactin. Up-regulated proteins included the antioxidants
superoxide dismutase, thioredoxin, and cytochrome c
reductase. Oxidative stress can also lead to dysfunction
of the proteasome and is implicated in PD pathogenesis
(Gu et al. 2005). Indeed, as a result of N-α-syn stimulation
the proteasome 26S subunit was decreased in these cell
lysates, although ubiquitin and the ubiquitin conjugating enzyme E2N were increased, suggesting that the microglia may be compensating for decreased proteasomal
activity (Table 3).
Neuroinflammatory Parkinson’s disease
phenotype
Analysis of the proteome of N-α-syn-stimulated microglia revealed the induction of NF-κB-related signaling pathways and initiation of several proteins involved
in the cellular response to inflammation and oxidative
stress. To investigate whether differential expression of
proteins identified in our proteomic analyses of in vitro
stimulated microglia was reflected in PD, protein expression of lysates prepared from the SN and BG (data not
shown) of control and PD brains were assessed by western blot assays (Figure 7). Proteins increased in abundance within the secretome as a result of N-α-syn stimulation (A. D. Reynolds, I. Kadiu, S. G. Garg, J. G. Glanzer,
T. Nordgen, R. Banerjee, P. Ciborowski, and H. E. Gendelman) were cross-validated in PD patients including
calmodulin and the redox-associated secreted proteins
biliverdin reductase and thioredoxin; whereas, secretion

b

16
3.8

NCBI Entrez GeneID.

of the regulatory proteins glatectin-3 and 14-3-3σ, structural protein actin, and the redox protein glutathione-Stransferase were decreased following N-α-syn stimulation. These analyses verified the increased expression of
calmodulin as well as the antioxidant biliverdin reductase in the SN of PD compared with age-matched controls without neurological disease. Actin expression appeared decreased in PD brains relative to controls, which
coincided with our analysis of the N-α-syn-stimulated
microglia secretome. In contrast to our in vitro results,
expression of 14-3-3σ and galectin 3 were increased in
PD brains. Glutathione-S-transferase expression was decreased in PD brains relative to control. Although expression of thioredoxin did not appear to be different within
the SN, expression in the BG was significantly decreased
in PD (data not shown). Proteins that were identified in
the proteome of N-α-syn-stimulated microglia were, in
part, also cross-validated in SN of PD and control brains.
Akin to our laboratory model, expression of calmodulin
was increased whereas expression of α-enolase (data not
shown), l-plastin, α-tubulin, and actin were decreased
in PD relative to control. The discrepancies between the
cellular model and expression in the human tissue underscore the complexity of human disease and the multiple cell components that are involved. Indeed, comparing non-affected brains to PD brains may be misleading
as already the proportion of cellular components are different, especially at end stage where greater than 80% of
the dopaminergic neurons have died and substantial gliosis is present. However, overall these results support
that the molecular and biochemical analyses of N-α-syn
microglial activation appear, in part, applicable to human PD.
Discussion
Recent investigations (Biasini et al. 2004; Zhang et al.
2005; Zhou et al. 2005; Thomas et al. 2007) demonstrated
that aggregated N-α-syn induces a neurotoxic inflammatory microglial phenotype that accelerates the demise
of dopaminergic neurons, and as such, may contribute,
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Table 3. N-α-syn-stimulated microglial proteome
Protein name

Mw (Da)b

PIc

Accession
numberd

Time
(h)e

Proteins increased in N-α-syn-stimulated microglia cell lysates when compared with controls
Regulatory
  10 kDa Heat-shock protein, mitochondrial
  S100 calcium-binding protein A13
  Apoptosis-associated speck-like protein
containing a CARD
  Beclin-1
  Calmodulin
  Calreticulin
  Cystatin B
  Dynein light chain 2A
  Ef3-CaM
  Eukaryotic initiation factor 5A isoform I
variant D
  Fatty acid-binding protein
  Heat-shock 70 kDa protein 1A
  Heat-shock 70 kDa protein 1B
  Heat-shock 70 kDa protein 1L
  Histone H2B F
  Kinesin light chain 4
  Mitogen-activated protein-binding
protein-interacting protein
  Nucleophosmin 1
  SH3 domain-binding glutamic
acid-rich-like protein 3
  SWIPROSIN 1/EF hand domain
containing protein 2 (Efhd2)
  Ubiquitin
Structural/cytoskeletal
  Capg protein
  Capping protein
  Cofilin-1
  Destrin
  Myosin heavy
  Talin
  Tubulin alpha-1 chain
Redox
  Isovaleryl-CoA dehydrogenase
  Cytochrome c oxidase, subunit Vb
  Peroxiredoxin-1
  Peroxiredoxin-4
  Peroxiredoxin-5
  Superoxide dismutase
Enzymes
  Cathepsin C
  Cathepsin Z
  Ferritin heavy chain
  Hexosaminidase B
  Peptidyl-prolyl cis-trans isomerase A
  Ubiquitin-conjugating enzyme E2N
  Ubiquitin-conjugating E2 Q2
  Vacuolar ATP synthase subunit G1

Number of
peptidesf

Volume
ratiog

a

10 825
11 151

8.18
5.89

Q64433
P97352

8
8

6
2

3.45
5.57

21
51
16
47
11
10
16

459
534
706
995
039
852
578

5.26
4.89
4.09
4.33
6.82
6.86
4.04

O88597
O88597
P62156
P14211
Q62426
P62627
P99027

2
2
8
8
8
8
2

6
2
3
7
2
3
8

1.58
1.48
7.51
1.67
3.06
3.73
2.26

16
14
70
70
70
13
68

821
996
052
167
637
805
613

5.08
6.18
5.48
5.53
5.91
10.32
5.76

Q7L7L3
Q05816
Q9EPB4
P17879
P16627
P10853
Q5JQI4

4
2
4
4
8
2
8

2
3
2
2
2
2
2

1.51
3.17
1.43
1.79
1.79
4.07
1.85

13 472
32 558

5.3
4.62

Q9JHS3
Q5U438

8
8

2
9

4.75
1.68

10 470

5.02

Q91VW3

8

4

3.12

26 800
8560

5.07
6.56

Q8C845
P62990

8
8

2
2

2.06
4.88

39 240
38 691
18 401
18 378
223 083
110 842
50 152

6.73
6.73
8.26
8.2
5.64
5.94
4.94

P24452
Q3TNN6
P45592
Q9R0P3
P02564
Q3TBC3
P68361

8
4
2
8
4
2, 4
8

11
2
5
6
2
4
7

1.71
1.24
3.28
3.04
1.27
1.58
1.92

46
13
22
31
21
24

325
838
176
053
897
603

8.53
8.34
8.26
6.67
9.1
8.8

Q9JHI5
Q9D881
P35700
O08807
P99029
P09671

8
8
2
2
2
2

7
3
20
2
2
2

1.71
3.98
1.42
1.42
1.48
1.42

52
34
20
61
17
17
42
13

347
175
935
115
960
127
192
362

6.41
6.13
5.53
8.28
7.74
6.13
4.9
5.52

Q3TIF1
Q9ES94
P09528
P20060
P17742
P61089
Q7YQJ9
Q9D1K2

4
8
2
2
8
8
4
8

2
4
4
8
14
5
5
3

1.29
1.69
1.44
2.67
4.77
3.26
1.3
4.23
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Table 3. (continued)
Protein name

Mw (Da)b

PIc

Other
  Annexin A5
  39S ribosomal protein L12
  Apolipoprotein A
  Fatty acid-binding protein (E-FABP)
  Fibulin 2
  Heterogenous nuclear ribonucleoprotein K
  Prosaposin

35 752
21 695
35 853
15 006
126 414
50 976
61 086

4.83
9.34
5.56
6.18
4.55
5.39
5.11

Proteins decreased in N-α-syn-stimulated microglial cell lysates

Accession
numberd
P48036
Q9DB15
Q6GTX3
Q05816
Q3TGL4
P61979
Q3TID4

Time
(h)e
8
4
8
8
8
8
8

Number of
peptidesf
4
3
5
2
2
8
3

Volume
ratiog
1.7
1.26
1.73
3.52
5.57
1.69
10.1

a

Regulatory	 	 		 	 	 
  14-3-3 Protein epsilon
29 155
4.63
P62259
8
8
−3.33
  26S protease regulatory subunit 7
48 517
5.72
P46472
8
2
−2.4
  Acyl-CoA binding protein
9863
8.78
P31786
4
8
−3
  Adenylyl cyclase-associated protein 1
51 444
7.3
P40124
8
9
−1.9
  Centromere protein F
367 594
5.03
P49454
2
3
−1.68
  Chloride intracellular channel protein 1
26 865
5.09
Q9Z1Q5
8
3
−3.28
  Coronin1B
53 912
5.54
Q9WUM3
4
3
−1.26
  Eukaryotic translation initiation factor 3
35 586
5.69
Q3THA0
8
2
−3.32
  Galectin 3
27 384
8.5
P16110
4
13
−2.34
  Heterogenous nuclear
ribonucleoproteins A2/B1
35 992
8.67
O88569
2
5
−1.61
  Macrophage Migration Inhibitory factor
12 373
7.28
P34883
8
3
−2.03
  Nuclear migration protein nudC
38 334
5.17
O35685
8
7
−4.13
  Programmed cell death 6-interacting protein 96 010
6.15
Q9WU78
4
8
−1.25
  SH3 domine-binding Glutamic
acid-rich-like protein
10 477
5.02
Q91VW3
8
12
−1.81
  Synaptotagmin-like protein 2
106 806
6.14
Q99N50
2
2
−1.46
Structural/cytoskeletal	 	 		 	 	 
  Beta-actin
41 737
5.78
P60710
4
26
−3.69
  Coronin-1A
50 989
6.05
O89053
8
10
−2.4
  Desmin
53 334
5.21
P31001
8
13
−3.25
  Gamma actin-like protein
43 572
5.11
Q9QZ83
8
27
−4.03
  Gelsolin
80 712
5.47
Q3U9Q8
8
7
−3.3
  L Plastin
70 018
5.2
Q61233
8
15
−2.58
  MFLJ00343 protein
205 326
5.6
Q6KAM8
8
17
−2.12
  Profilin-1
14 816
8.5
P62962
8
7
−1.35
  Tropomodulin
40 441
5.02
Q3KP84
8
2
−4.13
  Tropomysin-3
33 149
4.73
P21107
4
10
−1.25
  Tubulin alpha 4
49 761
4.95
Q3TY31
8
7
−3.23
  Tubulin alpha 6
49 907
4.96
QTIZ0
8
9
−3.25
  Vimentin
53 689
5.03
Q3TFD9
8
88
−3.38
Redox	 	 		 	 	 
  Glutaredoxin 1
11 732
8.69
Q91V76
4
2
−1.7
  Thioredoxin domain containing 5
46 386
5.51
Q3TEE8
8
38
−4.24
Enzyme						
  α-Enolase
47 010
6.36
P17182
8
8
−2.4
  2’-5’ olygoadenylate synthetase 1F
42 270
7.09
Q8K465
2
7
−1.68
  3-ketoacyl-CoA thiolase A
43 935
8.74
Q921H8
8
3
−2.66
  Aconitase
98 152
5.98
Q42560
2
3
−1.59
  ATP synthase
59 751
9.16
Q53XX6
2
2
−1.55
  ATP synthase e chain
8099
9.34
Q06185
4
5
−1.52
  Carbonyl reductase
30 394
6.15
Q8K354
4
3
−1.27
  Cathepsin B
37 256
5.57
P10605
8
15
−3.34
  Cathepsin D
44 925
6.71
P18242
8
34
−3.68
  Cathepsin S
38 707
6.51
Q8BSZ5
4
3
−1.29
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Table 3. (continued)
Protein name

Mw (Da)b

PIc

Accession
numberd

Time
(h)e

Number of
peptidesf

  F1-ATPase alpha subunit
44 144
7.07
O78824
2
9
  Fructose-bisphosphate aldolase A
39 225
8.4
P05064
8
33
  Glutamate oxaloacetate transaminase 2
47 183
9.05
Q3TIP6
4
3
  Phosphomannomutase 2
27 625
6.01
Q9D1M5
4
3
  Succinyl-CoA ligase beta chain, mitochondrial 50 082
6.57
Q9Z219
8
3
  Transitional endoplasmic reticulum ATPase
53 524
4.14
Q01853
8
19
Other						
  Annexin A1
38 603
7.15
P10107
8
8
  Annexin A3
36 240
5.33
O35639
8
5
  28S ribosomal protein S12, mitochondrial
15 437
10.72
O35680
2
2
  Arcn1 protein
47 964
5.61
Q8R1S6
8
7
  Beta-galactoside-binding lectin
15 914
9.01
Q61357
4
7
  Centrosomal protein of 27 kDa
26 839
6.06
Q9CQS9
2
3
  Clathrin light chain B
25 171
4.56
Q6IRU5
2
3
  Density regulated protein
22 152
5.21
Q9CQJ6
8
2
  Fatty acid binding protein
14 996
6.18
Q05816
4
4
  Glycoprotein (transmembrane) nmb
63 577
7.88
Q3TAV1
8
2
  Gsn protein
80 763
5.52
Q6PAC1
8
13
  Histone H2A type 1
14 004
11.05
P22752
8
2
  Protective protein for beta-galactosidase
53 795
5.56
Q9D2D1
4
3
  Vinculin
116 586
5.77
Q64727
8
9

Volume
ratiog
−1.55
−2.66
−1.23
−1.3
−4.12
−3.31
−1.9
−1.93
−1.63
−1.93
−1.84
−1.68
−1.68
−3.48
−1.27
−3.13
−1.66
−5.46
−3.47
−1.82

a

The CID spectra were compared against those of the EMBL non-redundant protein database by using sequest (ThermoElectron,
San Jose, CA, USA). After filtering the results based on cross-correlation Xcorr (cutoffs of 2.0 for [M + H]1+, 2.5 for [M + 2H]2+,
and 3.0 for [M + 3H]3+), peptides with scores greater than 3000 and meeting delta cross-correlation scores (ΔCn) > 0.3, and
fragment ion numbers > 60% were deemed valid by these sequest criteria thresholds, which have been determined to afford
greater than 95% confidence level in peptide identification; b Theoretical molecular mass; c Isoelectric point; d Accession numbers for UniProt (accessible at http://www.ipr.uniprot.org/search/textSearch.shtml);e Hours following stimulation with N-α-syn;
f Number of peptides identified for each protein selected based on the above mentioned criteria; g Volume ratio indicates foldchange versus control.

in part, to PD progression. However, the mechanisms
underlying N-α-syn-mediated microglial neurotoxicity remain obscure. To investigate the means by which
N-α-syn-mediated microglial activation affects dopaminergic neurodegeneration, the molecular and biochemical signatures of N-α-syn-stimulated microglia were
investigated. This report now demonstrates that microglial stimulation with aggregated, nitrated α-syn leads
to a neuroinflammatory phenotype capable of mediating neuronal toxicity. These observations are consistent
with the notion that release of this protein from injured
neurons can lead to microglial activation and nigrostriatal degeneration, reflective of PD pathobiology. A key
component of this study was the integration of physiologic, genomic, and proteomic techniques to develop a
fingerprint of microglial cell activation following its interactions with N-α-syn. This microglia phenotype was
characterized by morphological changes, as well as alterations in both the transcriptome and proteome that
result in reactive microgliosis and secretion of bioactive
factors, which were neurotoxic. Moreover, our examination shows human correlates of disease while permitting

an integrated cross-disciplinary approach for describing
a microglial “fingerprint” that may be reminiscent of inflammatory processes in PD. The inflammatory microglial phenotype now shown follows its interaction with Nα-syn and may affect dopaminergic neurodegeneration.
Microglia normally function as debris scavengers, killers of microbial pathogens, regulators of the immune responses, and supporters of neuronal functions (Vilhardt
2005); all necessary for host defense. However, during
neurodegenerative diseases, their phenotype is altered
by uncontrolled activation. Substantial evidence for reactive microglia in and around dead or dying dopaminergic neurons in the SN of PD patients suggests that
microglial activation and concomitant secretion of neurotoxic factors play a role in the nigrostriatal degeneration that occurs in PD. Stimulation by environmental
cues that include aggregated proteins and inflammatory
factors often results in the robust secretion of toxic factors that accelerate neuronal injury and death (McGeer
and McGeer 1998; Liu and Hong 2003). Cytokines released from activated microglia bind their cognate receptor on dopaminergic neurons to activate signal trans-
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Figure 6. 2DE and LC-MS/MS analysis of the N-α-syn-stimulated microglia proteome. Fluorescence 2D DIGE analysis of N-αsyn-activated microglial cell lysates. Fluorescence 2D DIGE (2DE) analysis of activated microglial cell lysates at 2, 4, and 8 h after N-α-syn stimulation. Proteins from cell lysates of unstimulated microglia labeled with Cy3 appear green on the 2 dimensional
gels, while proteins of N-α-syn stimulated microglia labeled with Cy5 appear red, and proteins common to both appear yellow.
Three-dimensional DeCyder interpretation for six representative proteins per time-point are shown. The numbers correspond to
the protein spot labeled on gels. Analysis of spot distribution to locate and define protein spots (right panel). Protein spots from
samples of stimulated cell lysates were identified as decreased (blue), increased (red), or common (yellow) versus non-stimulated cell lysates. Spots picked for sequencing analysis with LC-MS/MS are shown in purple. Abbreviations: HSP70, heat-shock
protein 70; Cyt c oxidase, cytochrome c oxidase; SOD, superoxide dismutase. A complete listing of all proteins identified through
2DE is contained within Table 3.

duction pathways resulting in apoptosis or necrosis. The
persistent activation of microglia in response to dopaminergic neuron injury has been investigated extensively
using the neurotoxin, MPTP. Work from several laboratories has documented that microglia activation accounts
for ~ 90% of MPTP-induced neuronal death (Wu et al.
2003; McGeer and McGeer 2004). Furthermore, studies
show MPTP neurotoxicity may be attenuated in mice unable to mount pro-inflammatory responses (Feng et al.
2002; Sriram et al. 2002; Teismann et al. 2003; Wu et al.

2003), by treatment with anti-inflammatory drugs (Liu et
al. 2006) and antioxidants (Zbarsky et al. 2005), blockage
of the NF-κB pathway (Ghosh et al. 2007), or by induction of a regulatory T-cell response (Benner et al. 2004;
Laurie et al. 2007; Reynolds et al. 2007); all converging on
attenuating microglial activation. In contrast, exacerbation of microglial activation by infiltrating effector lymphocytes to modified self-peptides may worsen MPTPinduced neurodegeneration (E. J. Benner, R. Banerjee, A.
D. Reynolds, S. Sherman, V. M. Pisarev, V. Tsiperson, C.
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Figure 7. N-α-syn-stimulated microglial proteins in PD brain tissue. Immunoblot identification of proteins in the SN and BG of
PD brains that were previously observed in N-α-syn-stimulated microglia. This includes 14-3-3σ, calmodulin, galectin-3, l-plastin, actin, tubulin, glutathione-S-transferase, thioredoxin, and biliverdin reductase. The proteins are divided into regulatory, cytoskeleton, or redox functions. The mean densitometric values were determined with ImageJ software and normalized to GAPDH expression in the same sample (bottom). Values are represented as the mean density ± SEM for four patients/group and p-values
of Student’s t-test of pair-wise comparisons of densities from Control (open bars) and PD (closed bars) patients are * p < 0.05
(** p < 0.05 and congruent results with the N-α-syn-microglial proteomic and western blot assays).

Nemacheck, P. Ciborowski, S. Przedborski, R. L. Mosley,
and H. E. Gendelman, unpublished data).
Generation of reactive molecular species by microglia,
as well as changes that occur during dopamine metabolism and mitochondrial function can result in oxidation
and nitration of proteins, DNA modifications, and lipid
peroxidation. Oxidation and nitration of α-syn leads to
formation of aggregates and the stabilization of assembled filaments found to be a major component of LBs,
the hallmark lesions of PD. The results of the present
study, as well as research performed by others (Biasini
et al. 2004; Zhang et al. 2005; Zhou et al. 2005; Thomas et
al. 2007) support the hypothesis that microglia activated
by N-α-syn is a component of an inflammatory cascade
that perpetuates nigrostriatal degeneration in PD. First,
nitrated α-syn was identified in extracts from the SN of
PD patients in copious concentrations relative to control
and AD brains. Second, α-syn aggregates released from

LB during dopaminergic neuronal death can interact
with adjacent microglial cells found in abundance within
the SNpc of PD patients (Spillantini et al. 1997; McGeer
and McGeer 1998; Croisier et al. 2005). Alternatively, αsyn may also be released or secreted from the cytosol of
dopaminergic cells into the extracellular environment
where it is more prone to aggregation and oxidative
damage (Kakimura et al. 2001; Lee et al. 2005; Sung et al.
2005). Third, microglial activation is associated with degenerating dopaminergic neurons and deposition of αsyn in the SN of PD patients (Croisier et al. 2005). Fourth,
native and nitrated α-syn activate microglia with release
of ROS and induce neurotoxicity as shown herein and
by others (Zhang et al. 2005; Thomas et al. 2007). Fifth, recent evidence supports that N-α-syn drains to the cervical lymph nodes, availing it for processing and presentation by antigen-presenting cells to the adaptive immune
system, which in turn can circumvent or break immu-
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nological tolerance to direct immune responses that possibly contribute to prolonged microglial activation and
neurodegeneration (E. J. Benner, R. Banerjee, A. D. Reynolds, S. Sherman, V. M. Pisarev, V. Tsiperson, C. Nemacheck, P. Ciborowski, S. Przedborski, R. L. Mosley, and
H. E. Gendelman, unpublished data). Moreover, α-syn
and its modified forms are present in extracellular biological fluids including human plasma (El-Agnaf et al.
2003) and are proposed as biomarkers for disease (Fjorback et al. 2007). Evidence of systemic complications associated with PD including abnormal gastrointestinal
function (Bassotti et al. 2000), cardiac denervation, and
orthostatic hypotension (Taki et al. 2000; Goldstein et al.
2005) further suggest a peripheral component in disease.
Taken together, this work extends those of others (Wang
et al. 2005; Zhou et al. 2005; McLaughlin et al. 2006). By using proteomic analyses for examination of the activated
microglial proteome it provides human disease correlates while permitting an integrated cross-disciplinary
proteomic approach towards elucidating a PD microglial “fingerprint.” The work provides evidence that such
a profile is inflammatory and may be linked to neurotoxicity. However, one must exert caution in over interpreting these experimental results. Nonetheless, whether or
not these findings are directly linked to the pathogenesis of PD will certainly require further study. Although
clear evidence is provided that microglial activation is
part of PD whether this process is a secondary by-product of ongoing neurodegeneration or a primary inducer
of disease remains uncertain.
Parallels are demonstrated herein between N-α-syn
and LPS for microglial activation and support a commonality for innate immune responses in disease. The
findings suggest that pro-inflammatory processes may
be common amongst mononuclear phagocytes that see
disparate activators. LPS is a strong activator of microglia both in vivo and in vitro. A single systemic exposure
to LPS can lead to neuroinflammation associated with
increased expression of pro-inflammatory cytokines,
NADPH oxidase-mediated release of superoxide (Gao et
al. 2002), and activation of the NF-κB pathway (Qin et al.
2007) resulting in neurodegeneration. Microglial activation by LPS and N-α-syn were associated with induction
of the ΝF-κB and mitogen activation pathways, characteristic of an inflammatory phenotype. However, key differences in the inflammatory responses induced by LPS
or N-α-syn were identified, including genes involved in
signal transduction and apoptosis, as well as induction
of an inflammatory response that was greater in magnitude after stimulation with LPS compared with that of
N-α-syn. It is possible that the differences in transcription may be dose or pathway dependent as the stimulatory capacity and pathways activated by the two stimuli
may differ significantly. Having demonstrated that N-αsyn stimulation induces microglial activation, this model
may be used to study PD and reflect the unique molecu-
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lar changes that occur during disease progression.
Our finding suggests that modifications to α-syn may
be a common denominator for microglial activation in
sporadic and familial PD. These observations also identify prospective pathways that are associated with PD
and as such uncover potential targets for therapeutic intervention. For instance, identification of NF-κB activation by microglia in response to divergent stimuli suggests that activation of NF-κB and its related signaling
pathways may be a key component in the inflammatory
response leading to neuronal death. The microglial response to N-α-syn was linked to neurotoxicity. Nonetheless, we also showed proteomic fingerprints that were
potentially protective. These include antioxidants and
growth factors. Although considered to be a necessary
component of CNS homeostasis, the potentially protective microglia mechanisms are lost as PD progresses uncontrolled. Furthermore, the similarities and differences
found between the acute in vitro model of N-α-syn microglial stimulation and what is present in PD brains
support that ongoing inflammatory responses present
in disease may affect CNS protective responses. The observations of sustained NF-κB activation and differential
expression of regulatory, structural, and redox proteins
at end-stage disease support, in part, a persistent inflammatory process that could affect dopaminergic loss.
In summary, a mechanistic role for aggregated N-αsyn in stimulating a neurotoxic microglial phenotype
was observed. In this ‘potential’ scheme, a pathogenic
paracrine loop of immune activation occurs consisting
of dopaminergic neuronal injury or death, release of aggregated N-α-syn from the cytosol or LB either through
exocytosis or neuronal degeneration into the extracellular milieu, microglial activation with release of toxic
factors which, may ultimately lead to further neuronal
injury and sustained α-syn release. Regardless of concurrent pathogenic events in PD, which initiate dopaminergic degeneration or the mechanisms associated with
activation by N-α-syn, the resultant activation of resident microglia could, in part, perpetuate neuronal injury and subsequent disease progression. Thus, the perpetual presence of activated microglia, left uncontrolled,
may consistently confound PD therapies. Our investigations also provide a novel approach towards elucidating cellular immune responses for neurodegeneration
and suggest potential molecular targets to slow disease
processes.
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